ChiCTR2300075752 版本V1.0 版本创建时间2023/09/14 14:42:01 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300075752 

最近更新日期:

Date of Last Refreshed on:

2023-09-14 14:41:41 

注册时间:

Date of Registration:

2023-09-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

艾司氯胺酮或羟考酮或舒芬太尼对腹腔镜胆囊切除术围手术期镇痛效果:一项前瞻性随机临床试验

Public title:

Perioperative Analgesic Effects of Esketamine or Oxycodone or Sufentanil for Laparoscopic Cholecystectomy: A Prospective, Randomized, Clinical Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾司氯胺酮或羟考酮或舒芬太尼对腹腔镜胆囊切除术围手术期镇痛效果:一项前瞻性随机临床试验

Scientific title:

Perioperative Analgesic Effects of Esketamine or Oxycodone or Sufentanil for Laparoscopic Cholecystectomy: A Prospective, Randomized, Clinical Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

殷德坤 

研究负责人:

殷德坤 

Applicant:

Dekun Yin 

Study leader:

Dekun Yin 

申请注册联系人电话:

Applicant telephone:

+86 158 0511 0243

研究负责人电话:

Study leader's
telephone:

+86 158 0511 0243

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

153761717@qq.com

研究负责人电子邮件:

Study leader's E-mail:

153761717@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省盐城阜宁县阜城大街111号

研究负责人通讯地址:

江苏省盐城阜宁县阜城大街111号

Applicant address:

111 Fucheng Street, Funing County, Yancheng, Jiangsu, China

Study leader's address:

111 Fucheng Street, Funing County, Yancheng, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省阜宁县人民医院

Applicant's institution:

Funing People's Hospital of Jiangsu Province

研究负责人所在单位:

江苏省阜宁县人民医院

Affiliation of the Leader:

Funing People's Hospital of Jiangsu Province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20230823

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

阜宁县人民医院伦理委员会

Name of the ethic committee:

Clinical Trials Ethics Committee of Funing People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-08-23 00:00:00

伦理委员会联系人:

梁廷红

Contact Name of the ethic committee:

Tinghong Liang

伦理委员会联系地址:

江苏省盐城阜宁县阜城大街111号

Contact Address of the ethic committee:

111 Fucheng Street, Funing County, Yancheng, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 138 6140 3360

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省阜宁县人民医院

Primary sponsor:

Funing People's Hospital of Jiangsu Province

研究实施负责(组长)单位地址:

江苏省阜宁县阜城大街111号

Primary sponsor's address:

111 Fucheng Street, Funing County, Yancheng, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

盐城

Country:

China

Province:

Jiangsu

City:

Yancheng

单位(医院):

阜宁县人民医院

具体地址:

阜宁县阜城大街111号

Institution
hospital:

Funing People's Hospital of Jiangsu Province

Address:

111 Fucheng Street, Funing County

经费或物资来源:

阜宁县人民医院科研基金

Source(s) of funding:

Research Fund of Funing People's Hospital of Jiangsu Province

研究疾病:

胆囊疾病  

Target disease:

gallbladder and biliary diseases.

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察艾司氯胺酮或羟考酮治疗腹腔镜胆囊切除术患者切口痛、内脏痛、肩部疼痛的效果。  

Objectives of Study:

Perioperative Analgesic Effects of Esketamine or Oxycodone or Sufentanil for Laparoscopic Cholecystectomy, including incision pain, visceral pain and referred pain (shoulder pain).

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

本院普外科收治的胆囊疾病患者,拟行择期下腹腔镜下胆囊切除术,年龄18-65岁,性别不限,(ASA)评分为I或II、体重指数(BMI)为18-30 kg/m2。

Inclusion criteria

All the patients included in this review underwent elective laparoscopic cholecystectomy. 1.male and female patients between 18 and 65 years of age; 2.American Society of Anesthesiology (ASA) score of I or II ; 3.body mass index (BMI) of 18–30 kg/m2;

排除标准:

1、非计划或紧急手术; 2、心功能不全(EF < 30%)或严重肺部疾病(I型或II型呼衰); 3、合并精神疾病、认知功能异常、长期服用抗精神病类药物或吸毒者; 4、对研究所用药物有过敏或禁忌症者 5、有神经阻滞穿刺禁忌症,或不能耐受神经阻滞穿刺者; 6、长期存在疼痛或神经病理性疼痛者; 7、存在胆囊穿孔胆结石并发症、弥漫性腹膜炎或急性化脓性胆管炎的患者。 8、文盲或不能理解研究中的评分。

Exclusion criteria:

1.unplanned emergency surgery; 2.severe cardiac insufficiency(EF < 30%) or serious lung diseases( type I or II respiratory failure); 3.mental illness or diminished cognitive function, or taking long-term antipsychoticor related drugs, or drug users; 4.allergies or contraindications to any of the study drugs; 5.Patients who had contraindications to nerve block, and can‐not tolerate a phrenic nerve block. 6. long-standing pain or neuropathic pain; 7.gallstones with gallbladder perforation, diffuse peritonitis or acute pyogenic cholangitis; 8.illiterate, or understand the study scoring.

研究实施时间:

Study execute time:

From 2023-09-15 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-09-15 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

艾司氯胺酮组

样本量:

60

Group:

Esketamine group

Sample size:

干预措施:

麻醉诱导前给与艾司氯胺酮

干预措施代码:

Intervention:

intravenous esketamine before anesthesia induction

Intervention code:

组别:

羟考酮组

样本量:

60

Group:

Oxycodone group

Sample size:

干预措施:

麻醉诱导前给与羟考酮

干预措施代码:

Intervention:

intravenous oxycodone before anesthesia induction

Intervention code:

组别:

舒芬太尼组

样本量:

60

Group:

Sufentanil group

Sample size:

干预措施:

麻醉诱导前给与舒芬太尼

干预措施代码:

Intervention:

intravenous sufentanil before anesthesia induction

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

盐城 

Country:

China

Province:

Jiangsu

City:

Yancheng

单位(医院):

阜宁县人民医院 

单位级别:

三级 

Institution
hospital:

Funing People's Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

一般特征、人口学和临床特征

指标类型:

次要指标

Outcome:

General characteristics of the patients,Demographic and clinical characteristics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者围手术期情况

指标类型:

次要指标

Outcome:

the perioperative conditions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者疼痛情况(切口痛、内脏痛、肩部痛等)

指标类型:

主要指标

Outcome:

Pain conditions, including incision pain, visceral pain and referred pain (shoulder pain).

Type:

Primary indicator

测量时间点:

术后不同时间点

测量方法:

Measure time point of outcome:

the different time points after surgery

Measure method:

指标中文名:

患者苏醒期及术后情况

指标类型:

次要指标

Outcome:

Postoperative Situation and the wake-up period conditions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

使用随机数字表由专业统计人员提供,并由本临床实验中不参与给药和疗效观察的人员根据随机号提供相应药物的注射溶液。

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients were divided into the treatment group and the contrast group by random number table method by professionals.The formulas were decided according to the number by people not participating in clinical medication and observation.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲,受试者,麻醉医生,数据记录员和分析员均不知分组情况。

Blinding:

Double blind, patients, attending anesthesiologists, data recorder, and analyzer are blinded about group assignment.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

文章发表后邮件通讯作者索取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data are available on request to the corresponding author, after the manuscript published.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-09-14 14:41:41